Chronic Myeloid Leukemia | Clinical

Asciminib Improves Efficacy vs Other Third-Line Treatments in Chronic Phase CML

July 22, 2022

Data revealed that a longer time to treatment discontinuation seen with asciminib favored its relative tolerability, correlating with the better-observed safety profile, according to data presented at the International Society for Pharmacoeconomics and Outcomes Research 2022